AKT1 and renal cell carcinoma: Targeting the PI3K-Akt-mTOR signal transduction pathway mutated in RCC has had promising results in recent studies, and in unselected patients with metastatic RCC, mTOR inhibitors have been shown to have clinical efficacy and low toxicity [6].